The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients

Swiss Medical Weekly

Volumn 137, Issue 39-40, 2007, Pages 556-558

  Yavas, Ozlem ^a   Yazici, Mehmet ^a   Eren, Onder ^a   Oyan, Basak ^b  

^a SELCUK UNIVERSITY   (Turkey)

^b YEDITEPE UNIVERSITY   (Turkey)

Author keywords

Arrhythmia; Cardiotoxicity; Herceptin

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ELECTROCARDIOGRAM; HEART FUNCTION; HUMAN; METASTASIS; P WAVE; PROTEIN EXPRESSION; QT DISPERSION; QT INTERVAL; RR INTERVAL; SYSTOLIC BLOOD PRESSURE;

EID: 35348851892     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Carraway KL, 3rd, et al. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature. 1997;387(6632):512-6.
2. Slamon DJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82.
3. Slamon DJ, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707-12.
4. De Placido S, et al. c-erbB2 expression predicts tamoxifen efficacy in breast cancer patients. Breast Cancer Res Treat. 1998;52(1-3):55-64.
5. Paik S, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst. 2000;92(24):1991-8.
6. Thor AD, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90(18):1346-60.
7. Tokuda Y, et al. Trastuzumab (Herceptin). Gan To Kagaku Ryoho. 2002;29(4):645-52.
8. Yeon CH, Pegram MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs. 2005;23(5):391-409.
9. Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast. 2004;13(3):173-83.
10. Wong SF. Trastuzumab and cardiotoxicity: weighing the risks. Am J Health Syst Pharm. 2006;63(6):525.
11. Schneider JW, Chang AY, Garratt A. Trastuzumab cardiotoxicity: Speculations regarding pathophysiology and targets for further study. Semin Oncol. 2002;29(3 Suppl 11):22-8.
12. Morganroth J. Evaluation of the effect on cardiac repolarisation (QTc interval) of oncologic drugs. Ernst Schering Res Found Workshop. 2007;(59):171-84.
13. Morganroth J. Cardiac repolarisation and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther. 2007;81(1):108-13.
14. Antzelevitch C, Yan GX, Shimizu W. Transmural dispersion of repolarisation and arrhythmogenicity: the Brugada syndrome versus the long QT syndrome. J Electrocardiol. 1999;32(Suppl):158-65.
15. Chen A, Kusumoto FM. QT dispersion: much ado about something? Chest. 2004;125(6):1974-7.
16. Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J. 1990;63(6):342-4.
17. Perkiomaki JS, et al. Heart rate variability and dispersion of QT interval in patients with vulnerability to ventricular tachycardia and ventricular fibrillation after previous myocardial infarction. J Am Coll Cardiol. 1997;30(5):1331-8.
18. Uyarel H, et al. Acute alcohol intake and P-wave dispersion in healthy men. Anadolu Kardiyol Derg. 2005;5(4):289-93.
19. Dilaveris PE, et al. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J. 1998;135(5 Pt 1):733-8.
20. Gialafos JE. P-wave dispersion. Eur Heart J. 1999;20(4):317.
21. Meric-Bernstam F, Hung MC. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res. 2006;12(21):6326-30.
22. Seidman A, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215-21.